Last Price | 78.20 | Max Price | 109.00 |
Min Price | 78.20 | 1 Year return | -10.73 |
Sector | Health Care | Subsector | Pharmaceuticals |
Contact info:Country: France
Year | Turnover | Total sector | Market share |
---|---|---|---|
2019 | 396 | 615,670 | 0.06 % |
2020 | 427 | 638,104 | 0.07 % |
2021 | 521 | 727,997 | 0.07 % |
2022 | 540 | 787,317 | 0.07 % |
2023 | 0 | 0 | 0.00 % |
No Records Found
No Records Found
No Records Found
Vetoquinol mainly operates in the pharmaceutical sector. The global pharmaceutical companies gained over the past 10 years on average 75 percent. Measured since 2011 the sector is 147 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 75 percent.
The period between December 2015 and December 2016 was a good period for the investors. The stock gained almost 21 percent. Over the past 5 years the stock rose a massive 112,8 percent. Vetoquinol's revenues between 2011 and 2015 were quite similar and moved between 298,29 million euros and 342,61 million euros. During 2011 and 2015 Vetoquinol's net results were very volatile and fluctuated between 22,68 million euros and 27,18 million euros.
The French company paid out dividends in the past 5 years. On average Vetoquinol's dividend yield over the past 5 years was around 1,85 percent annually.
At the end of 2015 the pharmaceutical company's balance sheet was worth 412,48 million euros. 123,04 million euros (29,83 percent of the total balance sheet) was financed by debt.
At the end of 2015 the French company had around 11,86 million stocks listed on the stock exchange(s).
On this page you can find all Vetoquinol's financial reports. More information about Vetoquinol can be found it's website. .
Results |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|---|
Revenue |
343
|
350
|
352
|
368
|
396
|
427
|
Costs |
318
|
323
|
317
|
332
|
367
|
408
|
Profit |
24
|
28
|
35
|
36
|
29
|
19
|
Margin of profit |
7.05
|
7.94
|
9.89
|
9.85
|
7.22
|
4.50
|
ROI |
8.35
|
8.80
|
10.38
|
9.99
|
7.40
|
5.17
|
Balance |
2015
|
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|---|
Equity |
289
|
316
|
336
|
363
|
386
|
372
|
Debt |
123
|
123
|
108
|
102
|
125
|
274
|
Total assets |
412
|
439
|
444
|
466
|
511
|
646
|
Solvency |
70.17
|
72.05
|
75.60
|
77.99
|
75.54
|
57.54
|
Cash |
87
|
103
|
113
|
118
|
85
|
129
|
Cashflow |
39
|
43
|
41
|
38
|
52
|
92
|
Employees |
0
|
0
|
0
|
0
|
0
|
|
Revenue per employee |
0.0
|
0.0
|
0.0
|
0.0
|
0.0
|
|
Cashflow / Debt |
0.32
|
0.35
|
0.38
|
0.37
|
0.42
|
0.34
|
Details |
2016
|
2017
|
2018
|
2019
|
2020
|
---|---|---|---|---|---|
Price |
39.40
|
45.53
|
60.53
|
50.80
|
64.40
|
Eps |
2.35
|
2.94
|
3.06
|
2.42
|
1.63
|
Price/earnings-ratio |
16.77
|
15.49
|
19.78
|
20.99
|
47.98
|
Dividend |
0.43
|
0.46
|
0.48
|
0.38
|
0.50
|
Dividend % |
1.09 %
|
1.01 %
|
0.79 %
|
0.75 %
|
0.64 %
|
Payout % |
0.18
|
0.16
|
0.16
|
0.16
|
0.31
|
Book value |
26.69
|
28.31
|
30.66
|
32.65
|
31.43
|
Market to book |
0.68
|
0.62
|
0.51
|
0.64
|
0.40
|
Cashflow per stock |
3.64
|
3.48
|
3.20
|
4.40
|
7.80
|
Stocks |
12
|
12
|
12
|
12
|
12
|
Market Cap |
467.18
|
539.86
|
716.91
|
601.16
|
925.00
|
Date
|
Price
|
---|---|
29 Nov 2024
|
78.20
|
27 Nov 2024
|
78.40
|
13 Nov 2024
|
84.00
|
08 Nov 2024
|
79.80
|
05 Nov 2024
|
79.20
|
31 Oct 2024
|
80.60
|
29 Oct 2024
|
82.70
|
23 Oct 2024
|
83.10
|
19 Oct 2024
|
83.10
|
16 Oct 2024
|
86.00
|
14 Oct 2024
|
86.00
|
05 Oct 2024
|
85.00
|
02 Oct 2024
|
83.60
|
27 Sep 2024
|
85.30
|
20 Sep 2024
|
82.80
|
17 Sep 2024
|
82.60
|
13 Sep 2024
|
94.20
|
28 Aug 2024
|
94.00
|
26 Aug 2024
|
92.90
|
23 Aug 2024
|
95.80
|
11 Aug 2024
|
94.10
|
07 Aug 2024
|
96.90
|
05 Aug 2024
|
95.90
|
01 Aug 2024
|
100.80
|
30 Jul 2024
|
100.00
|
26 Jul 2024
|
99.90
|
23 Jul 2024
|
101.00
|
16 Jul 2024
|
99.10
|
10 Jul 2024
|
95.20
|
09 Jul 2024
|
94.30
|